FOLATE RECEPTOR TARGETED NARINGENIN GOLD NANOPARTICLES: ITS IN VIVO ANTICANCER AND ANTIOXIDANT POTENTIAL IN EHRLICH ASCITES CARCINOMA BEARING SWISS ALBINO MICE

Debjani Chatterjee, Ananya Pradhan, Rumi Mahata, Rimpa Malakar, Sounik Manna, Subhabrata Das, Ahana Sinha, Tanmoy Maity and Sujata Maiti Choudhury*

ABSTRACT

The present study reports the cancer preventing outcome of synthesized biogenic folate receptor targeted naringenin gold nanoparticles (NAR-AuNPs-F) under in vivo settings. Ehrlich ascites carcinoma (EAC) is rodent mammary adenocarcinoma having high rate of proliferation along with transplantation potential. Antitumor and antioxidant efficacy of NAR-AuNPs-F was studied in EAC ascites tumor model. NAR-AuNPs-F was treated intraperitoneally at the dose levels of 1.5 and 3 mg/kg body wt. for 14 consecutive days. 5-flurouracil (5-FU) was utilized here as standard drug (20mg/kg body wt.) Tumor volume and tumor cell count, mean survival time, increase in life span, haematological parameters were measured. After treatment with synthesized NAR-AuNPs-F in EAC bearing mice, tumour volume and viable tumour cell count were decreased. Altered parameters such as haematological and antioxidant parameters were restored towards normal. Furthermore the average survival time of the treated animal elevated significantly in compared to the untreated control animals. The NAR-AuNPs-F revealed an extraordinary dose-dependent cytotoxic and antitumor effect on EAC cells in vivo. Treatment of mice bearing EAC tumours intraperitoneally with NAR-AuNPs-F showed an anti-proliferative outcome on EAC cells, abridged ascites volume, and upheld mean survival time. These results indicate towards the promising potential of this green synergy of naringenin and its targeted gold nanoparticles in cancer therapeutics.

Keywords: Naringenin, Gold nanoparticles, Folate receptor, Anticancer and Antioxidant potential, Ehrlich ascites carcinoma, Mean survival time.